Amgen stock falls as analysts mull over weight loss drug’s bone density data
Publishing timestamp: 2024-11-12 18:15:09
Summary
Shares of Amgen fell after bone density loss data from early-stage trial on weight loss injection MariTide. Some analysts see potential safety risk, while others say more data needed. MariTide could be promising competitor in weight loss drug market. Wall Street awaits phase two trial results. Concerns raised about bone mineral density loss, but some analysts believe data is overreacted and effects may normalize over time.
Sentiment: MIXED
Tickers: LLY, AMGN, NVO, NOVO.B-DK,
Keywords: novo nordisk a/s, amgen inc, health care industry, biotech and pharmaceuticals, lilly drn, pharmaceuticals, biotechnology, business, business news,
Source: https://www.cnbc.com/2024/11/12/amgen-stock-falls-on-weight-loss-drugs-bone-density-loss-data.html